CAD patients | All CAD (n=6313) | CAD alone (n=4303) | CAD+AF (n=700) | HF+CAD (n=728) | HF+CAD+AF (n=582) |
An antithrombotic* drug for all patients with CAD | 99.0 | 99.4 reference | 98.3 p=0.017 | 98.6 p=0.044 | 97.6 p=0.001 |
A statin for all patients with CAD | 91.0 | 92.3 reference | 85.6 p<0.0001 | 90.4 p=0.106 | 84.2 p<0.0001 |
An ACE-I or ARB for patients with CAD if presence of other conditions (eg, HF, hypertension or diabetes) | 87.5 | 88.0 reference | 84.2 p=0.346 | 90.8 p=0.011 | 84.0 p=0.473 |
Patients with AF | All AF (n=4973) | AF alone (n=2604) | CAD+AF (n=700) | HF+AF (n=1087) | HF+CAD+AF (n=582) |
An oral anticoagulant for AF patients with a CHA2DS2-VASc score ≥2 for men and ≥3 for women | 81.7 | 80.9 reference | 71.9 p<0.0001 | 87.8 p<0.0001 | 85.1 p=0.015 |
Patients with HF | All HF (n=2910) | HF alone (n=513) | HF+CAD (n=728) | HF+AF (n=1087) | HF+CAD+AF (n=582) |
An ACE-I or ARB for HF patients with LVEF <40% | 90.9 | 93.2 reference | 93.0 p=0.939 | 87.3 p=0.091 | 89.2 p=0.210 |
A beta-blocker for HF patients with LVEF <40% | 91.0 | 89.8 reference | 93.0 p=0.261 | 93.0 p=0.314 | 87.6 p=0.527 |
An MRA for HF patients with LVEF ≤35% | 43.0 | 44.5 reference | 47.8 p=0.558 | 36.8 p=0.199 | 40.5 p=0.489 |
An ICD for HF patients with LVEF ≤35% | 39.9 | 31.3 reference | 48.2 p=0.002 | 30.2 p=0.846 | 43.6 p=0.033 |
Data are presented as the percentage of patients actually treated according to the recommendation out of the total number of patients relevant to this recommendation. Age-adjusted and sex-adjusted p values were obtained by logistic regression with the single-disease groups (CAD alone, AF alone and HF alone) as the references.
*Antiplatelet drug and/or oral anticoagulant.
ACE-I, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.